Business Context and Reporting Period
Alpha Tau Medical Ltd. furnished a Form 6-K for June 2022, dated June 22, 2022. The filing reports that the Company issued a press release titled “Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™.”
Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, liquidity, balance-sheet data, or other financial metrics.
Material Changes Versus Prior Period
The filing does not present comparative financial information or quantify changes versus a prior period.
Guidance, Outlook, Risks, and Unusual Items
- The reported operational milestone is the treatment of the first prostate cancer patient with Alpha DaRT™.
- The supplied filing text does not include the contents of Exhibit 99.1, so details regarding the treatment, clinical setting, efficacy, safety, follow-up, or development outlook are unavailable.
- The Form 6-K states that the information is furnished and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless expressly specified.
Investor Verification Items
- Obtain and review Exhibit 99.1 for the full details of the first prostate cancer treatment.
- Verify the applicable clinical protocol, patient status, endpoints, safety information, and expected next steps.
- Review the Company’s latest Form 20-F and other filings for financial condition, cash runway, funding requirements, and material risks.